Remember Battleship? What a game, although if you tried to play it with a modern, dopamine-dazzled child they’d no doubt ...
Initiating add-on therapy within 2 years of a myasthenia gravis (MG) diagnosis was associated with a stronger and more consistent clinical response, according to a new study published in the Journal ...
Dyne has aligned with the U.S. Food and Drug Administration (FDA) on the HARMONIA Phase 3 trial design and protocol. HARMONIA is intended to serve as a confirmatory trial to support conversion of ...
Mistras Group, Inc. (NYSE:MG) Q4 2025 Earnings Call Transcript March 5, 2026 Operator: Good day, everyone. My name is Luke, and I will be your conference operator today. At this time, I would like to ...
NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and ...
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified ...
Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 –– FREEDOM2 trial open in South Korea, Australia, and New Zealand –– Well-funded with ...
U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology -- Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New ...
BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. BV100 demonstrated a dose-proportional pharmacokinetic profile and was ...
Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript March 5, 2026 Altimmune, Inc. misses on earnings expectations. Reported EPS is $-0.27191 EPS, expectations were $-0.25. Operator: Good ...
China’s latest $43 million grant commitment signals a deliberate, strategic repositioning that Western donors and regional ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM ESTCompany ParticipantsJean-Paul Kress - Chairman ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results